| Literature DB >> 25027636 |
Angelika Gutenberg1, Martin D Nischwitz2, Bastian Gunawan2, Christina Enders2, Klaus Jung3, Markus Bergmann4, Wolfgang Feiden5, Rupert Egensperger6, Kathy Keyvani6, Dietmar Stolke7, Ulrich Sure7, Henry W S Schroeder8, Rolf Warzok9, Ralf Schober10, Jürgen Meixensberger11, Werner Paulus12, Hansdetlef Wassmann13, Wolfgang Stummer13, Ingmar Blumcke14, Michael Buchfelder15, Frank K H van Landeghem16, Peter Vajkoczy17, Marlis Günther18, Jens Bedke19, Alf Giese20, Veit Rohde21, Wolfgang Brück22, Laszlo Füzesi2, Bjoern Sander23.
Abstract
Synchronous (early) and metachronous (late) brain metastasis (BM) events of sporadic clear cell renal cell carcinoma (ccRCC) (n = 148) were retrospectively analyzed using comparative genomic hybridization (CGH). Using oncogenetic tree models and cluster analyses, chromosomal imbalances related to recurrence-free survival until BM (RFS-BM) were analyzed. Losses at 9p and 9q appeared to be hallmarks of metachronous BM events, whereas an absence of detectable chromosomal changes at 3p was often associated with synchronous BM events. Correspondingly, k-means clustering showed that cluster 1 cases generally exhibited low copy number chromosomal changes that did not involve 3p. Cluster 2 cases had a high occurrence of -9p/-9q (94-98%) deletions, whereas cluster 3 cases had a higher frequency of copy number changes, including loss at chromosome 14 (80%). The higher number of synchronous cases in cluster 1 was also associated with a significantly shorter RFS-BM compared with clusters 2 and 3 (P = 0.02). Conversely, a significantly longer RFS-BM was observed for cluster 2 versus clusters 1 and 3 (P = 0.02). Taken together, these data suggest that metachronous BM events of ccRCC are characterized by loss of chromosome 9, whereas synchronous BM events may form independently of detectable genetic changes at chromosomes 9 and 3p.Entities:
Keywords: Clear cell renal cell carcinoma; brain metastasis; chromosomal copy number alterations; comparative genomic hybridization (CGH); tumor progression
Mesh:
Substances:
Year: 2014 PMID: 25027636 DOI: 10.1016/j.cancergen.2014.05.004
Source DB: PubMed Journal: Cancer Genet